Recently, targeted therapy for malignant tumors has developed rapidly, but there is still no effective targeted therapy for advanced esophageal squamous cell carcinoma (ESCC). Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) is a key enzyme involved in folate metabolism and is closely related to the proliferation in many cancers. However, few studies have explored the expression of MTHFD2 in ESCC and its prognostic significance.
Background
Esophageal cancer ranks sixth worldwide in cancer-related deaths [1] . Recently, investigations showed that about 450 000 new patients were diagnosed with esophageal cancer each year, causing approximately 400 000 deaths worldwide [2] . Therefore, esophageal cancer is a disease with high incidence rates and poor prognosis. According to the published literature, China is a high-risk area for esophageal cancer, and the pathological type of most patients is esophageal squamous cell carcinoma (ESCC) [3] . In recent years, advances in molecular biology have improved cancer treatment and more and more targeted drugs have gradually begun to appear. The vast majority of targeted drugs have been exploited for treatment of tumors. However, drugs targeting ESCC still have limited efficacy. Novel therapeutic targets and prognostic biomarkers are urgently needed to improve the prognosis for patients with ESCC.
Methylenetetrahydrofolata dehydrogenase 2 (MTHFD2), also named methylenetrahydrofolata cyclohydrolase, was initially identified in Ehrlich ascites tumor cells in 1960 [4] . It is an essential enzyme in the mitochondria involved in cell activity and is encoded by genes on the human second chromosome [5] . MTHFD2 has a double function of formyltetrahydrofolate synthetase and cyclohydrolase [6] , and it is necessary for enabling the cell to proliferate rapidly [7, 8] . Recently, MTHFD2 has been shown to be highly expressed in liver cancer, breast cancer, and kidney cancer, and be associated with poor prognosis of patients [9] [10] [11] . The elevated expression of MTHFD2 has been proven to be closely related to the occurrence and development of tumors. However, there have been no relevant reports on the expression of MTHFD2 and its prognosis in ESCC.
First, we used a bioinformatics database to predict the expression of MTHFD2 in ESCC. Then, the expression levels of MTHFD2, Ki67, and P53 were detected by immunohistochemistry in ESCC tissues and the related normal tissues. Moreover, the chi-squared test was used to analyze the relationship between MTHFD2 expression and clinicopathological parameters. Kaplan-Meier univariate and Cox multivariate survival analysis were performed to evaluate the correlation between MTHFD2 expression and prognosis of ESCC patients.
Material and Methods

Bioinformatics analysis
To understand the feasibility of the experiment, the Oncomine database was used to predict the expression of MTHFD2 mRNA in ESCC in advance.
Patients and specimens
After approval by the Anhui Provincial Hospital and obtaining written informed consent from all subjects, research on the expression of MTHFD2 in ESCC was begun. A total of 78 histologically confirmed specimens of esophageal squamous cell carcinoma were collected from the Pathology Department of Anhui Provincial Hospital. These specimens were all from patients who underwent surgical resection of esophageal cancer in Anhui Provincial Hospital from January 2006 to October 2008. Follow-up lasted until July 2015. None of the patients received any treatment other than surgery, and the follow-up data were relatively complete. The clinicopathologic parameters of the patient included sex, age, pathological grading, lymph node metastasis, and TNM stage in patients. We obtained the TNM stage of patients and pathological grading of tissues according to the 7 th edition of the Esophageal Cancer Staging System jointly formulated by the Union for International Cancer Control (UICC) and the American Joint Commission on Cancer (AJCC). Among these 78 patients, cases 1-61 of ESCC pathological specimens had corresponding normal tissues, and cases 62-78 were only ESCC pathological specimens.
Immunohistochemistry
First, HE staining was performed to distinguish cancerous and adjacent noncancerous tissue specimens. Then, immunohistochemistry was applied to examine the expression levels of MTHFD2. Conventional paraffin sections were dewaxed with xylene and dehydrated with gradient ethanol. Afterwards, the sections were washed with phosphate-buffered saline (PBS) and incubated at 37°C and 3% H 2 O 2 for 10 min to inactivate endogenous peroxidase. After antigen retrieval with citrate buffer (pH 6.0), sections were blocked in 10% sheep serum for 10 min. The sections were incubated with anti-MTHFD2 antibody (1: 500, Abcam, UK) at 4°C overnight, and then incubated with biotin-labeled antibody (Dako, USA) for 30 min at room temperature. Finally, the sections were colored by 3,3-diaminobenzidine (DAB) and stained with hematoxylin. PBS was used as negative control instead of primary antibody. Pathological specimens were assessed for expression of ki67 and p53 by immunohistochemistry.
Determination of immunohistochemical results
Two pathologists independently evaluated the immunohistochemical results of all sections using a double-blind method. We evaluated the positive expression of the gene from the 2 aspects of staining intensity and the proportion of positive cells. The standards for staining intensity were as follows: 0 points (no staining); 1 point (light brown), 2 points (yellowish brown), and 3 points (dark brown) ( Figure 1 ). The percentage of positive tumor cells was classified as follows: Figure 2 ). Subsequently, by calculating the product of staining intensity and area score, patients were divided into the following 2 different expression groups: £6 was the low-expression group and >6 was the high-expression group [12] .
The results of ki67 and p53 were determined as described previously [13, 14] . Positive staining was defined as neutral or strong brown staining. The determination result of p53 was as follows: £15% was negative (0 points), 15-40% was medium expression (1 point), and >40% was high expression (2 points). Ki67 was determined as follows: £20% was negative (0 points), 21-50% was medium expression (1 point), and >50% was high expression (2 points).
Statistical analysis
We used SPSS 22.0 (IBM, Armonk, NY) software for statistical analysis. P value less than 0.05 was defined as statistical significance. Overall survival (OS) was calculated as the time from the start of surgery to the time of death or to the end of follow-up. The chi-squared test was used to analyze the relationship between MTHFD2 expression and clinicopathological parameters. Kaplan-Meier and log-rank tests were used to univariate survival analysis. The correlation between the 2 variables was calculated by Spearman's rank correlation analysis. Multivariate analysis of prognostic factors was performed by Cox multivariate analysis.
Results
Bioinformatics prediction results
The Oncomine database was used to predict the expression level of MTHFD2 mRNA in ESCC and normal esophageal tissue. Compared with the normal group, the expression level of MTHFD2 mRNA was significantly higher in ESCC tissues (P<0.05) ( Figure 3A , 3B).
Expression of MTHFD2 and its relationship with clinicopathological parameters
The expression of MTHFD2 in patients with ESCC was detected by immunohistochemical staining. Immunohistochemistry of the pathological specimens of 78 ESCC patients suggested that the proteins expressed by MTHFD2 were mainly distributed in cytoplasm. In accordance with the immunohistochemical result, MTHFD2 was highly expressed in ESCC specimens at a rate of 74.36%, but not in normal esophageal tissue (P<0.001, Table 1 , Figure 4A , 4B). The relationship between MTHFD2 expression levels and ESCC patients' clinicopathological parameters are listed in Table 2 . The results showed that the expression of MTHFD2 was significantly correlated with the pathological grading (P=0.02) and TNM stage (P=0.019) of patients. However, there were no significant correlations between the MTHFD2 protein expression levels and the patient age, lymph node metastasis, or sex. Figure 5A ). TNM stage was correlated with the prognosis of patients, and patients with TNM stage III/IV had worse OS than those with TNM stage I/II (95% CI 36.374-60.826 vs. 15.932-29.280, P=0.004; Figure 5B ). However, sex, age, pathological grading, and presence of lymph node metastasis were not associated with OS (P>0.05, Figure 5C-5F ). Furthermore, Cox multivariate regression analysis showed that high expression of MTHFD2 was closely associated with the prognosis of patients, which could be used as an independent prognostic indicator for predicting ESCC (Table 3) .
Expression of MTHFD2 and clinical prognosis of patients
Relationship between high expression of MTHFD2 and ki67 and p53 in ESCC
We also used immunohistochemical staining to assess the expression of ki67 and p53 in ESCC. As shown in Figure 6 , tumors with high expression of MTHFD2 had significantly higher expression of ki67 and p53. Spearman's rank correlation analysis showed that the expression of MTHFD2 was significantly positively correlated between ki67 (r=0.441, P<0.001, Table 4 ) and p53 (r=0.249, P=0.028, Table 5 ) in ESCC tissues. 
Discussion
Diagnosis and treatment of esophageal squamous cell carcinoma currently mainly focuses on early detection, early surgery, and radical radiotherapy. The clinical research results of targeted therapy drugs for patients with advanced esophageal squamous cell carcinoma are not satisfactory. The heterogeneity of esophageal cancer and the emergence of drug resistance in the process of treatment can lead to poor efficacy. At present, the underlying molecular mechanism of ESCC pathogenesis is still unclear. Thus, to improve the survival time of ESCC patients, it is urgent to find molecular targets and biomarkers that predict prognosis in the treatment of advanced esophageal squamous cell carcinoma.
MTHFD2 is closely involved in folate metabolism during cell proliferation. Tumor cells have a rapid anabolic process that is inseparable from folate metabolism [15] . MTHFD2 has been repeatedly confirmed at the protein level to be associated with tumorigenesis, progression, and prognosis of patients, including those with highly aggressive pancreatic cancer [16] . In the present study, we observed that MTHFD2 was expressed at higher levels in ESCC tissue than in esophageal normal tissues. Therefore, we speculated that MTHFD2 plays a vital role in tumor initiation and progression. MTHFD2 was recently reported to be closely involved in the rapid growth of cells, such as embryonic cells and cancer cells, by synthesizing high levels of purine [7, 8] . Mounting evidence shows that MTHFD2 is a cancer-related metabolic enzyme. Researchers have shown that the expression of MTHFD2 mRNA and protein are upregulated in rapidly proliferating malignant tumor cells [12, 17] . Moreover, there is evidence that inhibiting the expression of MTHFD2 effectively decreases the proliferation of tumor cells. For instance, Selcuklu et al. found that knockout of the MTHFD2 gene leads to the death of breast cancer cells and reduces invasion and migration [18] . Similarly, MTHFD2 was reported to promote the growth and metastasis of colorectal cancer cells, and MTHFD2 knockdown clearly inhibits tumor growth [19] . Furthermore, recent studies have demonstrated that many micro-RNAs in tumor cell pathways play an antitumor role by inhibiting the expression of MTHFD2, such as mir-940 [20] , mir-504-3p [21] , and mirRNA-92a [22] . The studies above indicate that MTHFD2 is closely involved in the occurrence and development of tumors. However, most previous studies did not clarify the relationship between MTHFD2 expression and tumor prognosis and/or clinicopathological parameters of ESCC.
Through bioinformatics, we observed that the expression level of MTHFD2 mRNA in ESCC tissues was significantly higher than that in the normal group. To verify this result, we conducted this study. The experimental results objectively showed that MTHFD2 was highly expressed in ESCC compared with the corresponding normal tissues, which was consistent with the bioinformatics results at the protein level. At present, ki67 is the most widely used markers of tumor proliferation. As a tumor suppressor gene, p53 regulates cell proliferation, but the mutant p53 is closely involved in the proliferation of various tumor cells and is related to poor prognosis of patients [23] . A previous study showed that ki67 and p53 were related to the occurrence and development of esophageal cancer [24] . Thus, to verify whether there is a relationship between MTHFD2 protein and tumor proliferation, we compared the protein expressions of MTHFD2, ki67, and p53. The results indicated that tumor tissues with high expression of MTHFD2 expressed higher ki67 and p53 than those with low MTHFD2. Further analysis by Spearman's rank correlation test showed that MTHFD2 was positively correlated with ki67.
Interestingly, MTHFD2 was also positively correlated with p53.
Our results suggest that the high expression of MTHFD2 promotes the proliferation of tumor cells and inhibits apoptosis, resulting in poor prognosis of patients.
Of course, the present study has certain limitations. This study was only a retrospective study with a small sample size, which might be statistically biased. Larger experimental studies may be needed to obtain more accurate results. In addition, we only used the immunohistochemical staining, which is a semi-quantitative method, and some other quantitative methods like Western blot or qRT-PCR analysis are needed for more stronger evidence.
Conclusions
We found that MTHFD2 was highly expressed in ESCC and was closely related to poor prognosis. The study shows that MTHFD2 is an independent risk factor in ESCC, and is a potential biomarker for predicting ESCC in the future.
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